Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and
5 hours ago
- #triplet therapy
- #prostate cancer
- #Bayesian analysis
- Comparison of triplet (androgen-deprivation therapy + docetaxel + androgen receptor pathway inhibitor) versus doublet therapy (androgen-deprivation therapy + androgen receptor pathway inhibitor) in Japanese patients with high-volume metastatic hormone-sensitive prostate cancer.
- Primary endpoint was time to castration-resistant prostate cancer (CRPC), analyzed using overlap-weighted Cox models and restricted mean survival time (RMST) at 12 and 24 months.
- No statistically significant difference found between triplet and doublet therapy in time to CRPC (hazard ratio: 0.81, 95% CI: 0.31-2.12).
- Exploratory Bayesian synthesis suggested a modest advantage for triplet therapy in CRPC-free RMST, but results remain hypothesis-generating.
- Study utilized data from the YUSHIMA registry and incorporated external phase III trial data for Bayesian analysis.